Hualan Biological Vaccine
Xinxiang City, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A leading Chinese vaccine manufacturer focused on influenza and other infectious disease vaccines, with WHO pre-qualified products.
Infectious Disease
Technology Platform
Platform for developing split-virion inactivated viral vaccines and bacterial polysaccharide vaccines, with a Hansenula polymorpha yeast system for recombinant protein expression.
Opportunities
Growth opportunities include expansion of its product portfolio with newly launched vaccines (tetanus, rabies), increased international sales driven by WHO pre-qualification, and leveraging its rapid-response platform for future pandemic influenza strains.
Risk Factors
Key risks include intense competition in the Chinese vaccine market, pricing pressure from national immunization programs, and reliance on seasonal influenza demand which can be variable.
Regulatory hurdles for international expansion also persist.
Competitive Landscape
Competes with large Chinese vaccine firms like Sinovac Biotech and China National Biotec Group (CNBG). Differentiates through specialized focus on influenza vaccines, proven rapid development capability for pandemic strains, and WHO pre-qualification status facilitating export potential.